Abstracts tagged "Comorbidity"

Abstract Number: 0169 • ACR Convergence 2025
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Sally Wetten¹, George Mu², Keele E. Wurst³, Roger A. Levy⁴, Ben Newth⁵, Svetlana I. Nihtyanova⁶ and Elaine Irving⁷, ¹GSK, Epidemiology, Stevenage, United Kingdom, ²GSK, Statistics, Collegeville, PA, ³GSK, Immunology and Emerging Epidemiology, Durham, NC, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, ⁶GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁷GSK, Clinical, Stevenage, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 1995 • ACR Convergence 2025
The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Chio Yokose¹, Natalie McCormick², Jiaqi Wang², Sharan Rai³, leo lu⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
Abstract Number: 1271 • ACR Convergence 2025
Overcoming Obstacles to Care: Survey of Adult Patients with Idiopathic Inflammatory Myopathies (IIM)
Saloni Patolia¹, Carolina Alvarez², Jessica Grant³, Paul Mihas⁴, Todd Schwartz⁵, Galen Foulke⁶, Amanda Nelson⁵ and Astia Allenzara⁵, ¹UNC Rheumatology, Durham, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³Odum Institute for Reseach in Social Science, Chapel Hill, NC, ⁴Odum Institute for Reseach in Social Science, Chapel Hill, ⁵Thurston Arthritis Research Center, Chapel Hill, ⁶Penn State Health, Hershey, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogenous autoimmune diseases requiring coordinated, patient-centered care. Understanding patient perspectives on diagnosis, treatment, health screening, and barriers to care…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 2422 • ACR Convergence 2025
Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
Oihane Ibarguengoitia-Barrena¹, Leyre Riancho Zarrabeitia², Iñigo Rúa-Figueroa³, Karen Roberts⁴, Victor Martinez-Taboada⁵, Raúl Menor Almagro⁶, Belén Serrano-Benavente⁷, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernández-Nebro¹⁰, Maria Esther Ruiz Lucea¹¹, Jaime Calvo¹², Jose Francisco Garcia Llorente¹³, EVA GLORIA TOMERO MURIEL¹⁴, Maria Esther Uriarte¹⁵, Mercedes Freire González¹⁶, Angela Pecondón-Español¹⁷, Javier García-Fernández¹⁸, Lorena Expósito-Pérez¹⁹, Monica Ibañez Barcelo²⁰, Elena Aurrecoechea²¹, Carlos Montilla²², Jose Rosas Gómez de Salazar²³, Maria Garcia-Villanueva²⁴, Rocío Caño²⁵, Francisco Javier Toyos²⁶, Francisco Javier Novoa²⁷, Clara Moriano²⁸, Gema Bonilla²⁹, Javier Narváez³⁰, Jose Luis Andreu³¹, Marta Arévalo-Salaet³², Loreto Horacda-Rubio³³, Tatiana Cobo-Ibáñez³⁴, Nuria Lozano Rivas³⁵, Cristina Bohorquez³⁶, Carlota Laura Iniguez Ubiaga³⁷, Eva salgado-Pérez³⁸, Vicente Torrente Segarra³⁹, CARLOS TAREK SALMAN MONTE⁴⁰, JOSE ELOY OLLER RODRIGUEZ⁴¹ and José María Pego-Reigosa⁴², ¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²Hospital Sierrallana, Santander, Spain, ³Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁴Buenos Aires Instituto, West Reading, CA, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Universitario Donostia, San Sebastian, Spain, ¹⁶⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁹University Clinical Hospital of Canarias, Tenerife, Spain, ²⁰Son Llàtzer University Hospital, Palma de Mallorca, Spain, ²¹Hospital Sierrallana, CANTABRIA, Spain, ²²Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Hospital Ramón y Cajal, Madrid, Spain, ²⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁶Virgen Macarena University Hospital,, Sevilla, Spain, ²⁷Hospital Insular de Gran Canaria, Las palmas, ²⁸Hospital León, LEON, Castilla y Leon, Spain, ²⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ³²Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Infanta Sofia Hospital, Madrid, Spain, ³⁵Hospital Clínico Universitario Virgen de la Arrixaca,, Murcia, Spain, ³⁶La Paz University Hospital, Alcalá De Henares, Spain, ³⁷SERV. REUMATOLOGIA, Lugo, Spain, ³⁸Complejo Hospitalario de Orense, Santiago de Composte, Spain, ³⁹Hospital Comarcal del Alt Penedes, Madrid, Spain, ⁴⁰Hospital del Mar, Barcelona, Spain, ⁴¹HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁴²Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where…
Abstract Number: 1993 • ACR Convergence 2025
Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Tingting Zhang¹, Christian W. Mende², Ashraf El-Meanawy³, Michael Pillinger⁴, Kaiding Zhu⁵, Bradley Marder⁶ and Brian Lamoreaux⁷, ¹Amgen, Inc., Thousand Oaks, ²University of California San Diego, San Diego, CA, ³Medical College of Wisconsin, Milwaukee, WI, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Amgen, Inc., San Francisco, CA, ⁶AMGEN, Inc, Denver, CO, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…
Abstract Number: 1224 • ACR Convergence 2025
Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients
Chukwuemelie Okeke¹, Queeneth Edwards², Ufuoma Mamoh³, Justin Riley Lam⁴ and Chekwubejah Uwakwe⁵, ¹Maimonides Medical Center, Brooklyn, NY, ²Department of Epidemiology and Biostatistics, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, ³Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁴Jefferson Einstein Hospital, Philadelphia, PA, ⁵Nnamdi Azikiwe University Teaching Hospital, Nigeria, Nnewi, Anambra, Nigeria
Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating condition characterized by widespread pain, fatigue, and cognitive disturbances. Despite the availability of FDA-approved treatments, real-world comparative effectiveness…
Abstract Number: 0154 • ACR Convergence 2025
Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
Diana Martins¹, George Mu², Elaine Irving³, Roger A. Levy⁴, Nisha Bhatt⁵ and Keele E. Wurst⁶, ¹GSK, Epidemiology, Toronto, ON, Canada, ²GSK, Statistics, Collegeville, PA, ³GSK, Clinical, Stevenage, United Kingdom, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Global Medical Affairs, Collegeville, PA, ⁶GSK, Immunology and Emerging Epidemiology, Durham, NC
Background/Purpose: Despite the high disease burden and reduced quality of life for patients with CTD-ILD, data on its incidence and prevalence – particularly by CTD…
Abstract Number: 2412 • ACR Convergence 2025
Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Maria Romero Noboa¹, Faria Sami², Almurtada Razok³ and Shahzad Ahmed Sami⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²The University of Alabama at Birmingham, Birmingham, AL, ³John H Stroger Jr Hospital of Cook County, Chicago, IL, ⁴DCH Regional Medical Center, Birmingham
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…
Abstract Number: 1920 • ACR Convergence 2025
Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Angeles Lopez-Olivio¹, Zhigang Duan², Huifang Lu³, Edwin J. Ostrin², Robert J. Volk², Ying Xu², Sharon H. Giordano⁴ and Hui Zhao⁴, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³UT MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for lung cancer. Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended for…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 0091 • ACR Convergence 2025
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities
Athena Chin¹, susan branford², Annabelle Small³, malcolm Smith¹, monika Kutyna⁴, Robert King⁵, Susanna Proudman⁶, Devendra Hiwase⁷ and Mihir Wechalekar⁸, ¹Flinders Medical Centre, KURRALTA PARK, South Australia, Australia, ²SA Pathology, Adelaide, ³Flinders University, Bedford Park, South Australia, Australia, ⁴South Australian Health and Medical Research Institute, Adelaide, ⁵Flinders Medical Centre, Adelaide, South Australia, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁷Royal Adelaide Hospital, Adelaide, ⁸Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations, at a variant allele frequency (VAF) < ![if…
Abstract Number: 2383 • ACR Convergence 2025
The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Cristina Reategui-Sokolova⁴, Claudia Elera-Fitzcarrald⁴, Cesar Pastor-Asurza⁵, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: The CCI has been associated with adverse health-related outcomes in SLE-patients worldwide. Its modified version, the age-adjusted CCI (ACCI) has been associated with organ…
Abstract Number: 1894 • ACR Convergence 2025
Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis
Jacob Riegler¹, Leah Santacroce², Karen H. Costenbader³ and Candace Feldman⁴, ¹Cambridge Health Alliance, Harvard Medical School, Somerville, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston
Background/Purpose: Opioid use disorder (OUD) is associated with high morbidity and mortality and in the U.S. in 2022, resulted in over 81,000 overdose deaths.1 However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].